International Patent Toolkit: PCT, National Stage, and Country Strategy

By Casey Scott McKay · 2024-06-14

Patents are territorial, the deadline to preserve foreign rights runs twelve months from the first filing, and nearly every expensive mistake in international patent practice is a date that passed. This toolkit runs the foreign filing decision from the priority deadline through national stage entry and annuities, and routes each stage to the Marksy documents that do the work. It explains what the treaty route actually buys, why the thirty-month deadline is the most useful deferral in patent practice and the most commonly misunderstood, and why absolute novelty abroad means a domestic grace period is not a plan. It covers country selection on manufacturing and enforcement rather than on market size alone, the translation and annuity costs that dominate the budget, and the utility model and validation options that change the arithmetic. It closes with the reading path, the authorities table, and the forms.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 14 June 2024 - Updated 7 May 2026 | Casey Scott McKay - marksy.us

Summary. Patents are territorial, the deadline to preserve foreign rights runs twelve months from the first filing, and nearly every expensive mistake in international patent practice is a date that passed. This toolkit runs the foreign filing decision from the priority deadline through national stage entry and annuities, and routes each stage to the Marksy documents that do the work. It explains what the treaty route actually buys, why the thirty-month deadline is the most useful deferral in patent practice and the most commonly misunderstood, and why absolute novelty abroad means a domestic grace period is not a plan. It covers country selection on manufacturing and enforcement rather than on market size alone, the translation and annuity costs that dominate the budget, and the utility model and validation options that change the arithmetic. It closes with the reading path, the authorities table, and the forms.

Keywords: paris convention priority · twelve-month deadline · patent cooperation treaty · international application · international search report · written opinion · chapter two demand · national stage entry · thirty-month deadline · direct filing · foreign filing license · absolute novelty · grace period differences · translation costs · annuities · country selection · european patent · utility models · validation · enforcement asymmetry

Start Here

Brennerman Optics filed a domestic application eleven months and two weeks ago. On a Monday, four things land on the same desk.

The chief financial officer asks what foreign filing will cost, having heard a number from a colleague that is either wildly high or wildly low depending on which countries are meant.

The chief technology officer mentions that the invention was described in a poster session at an optics conference fourteen months ago, and asks whether that matters.

Sales reports that the largest prospective customer manufactures in one country, assembles in a second, and sells into a third, and asks where the patent should be.

And the board wants to know whether the company should file "internationally," which is not a thing that exists.

Four questions, one deadline two weeks away, and a common misunderstanding: that there is an international patent. There is not. There are national patents, a treaty that defers the decision about which ones, and a priority right that expires.

This toolkit answers three questions.

What is the deadline, and what does it preserve? Twelve months from the first filing to claim priority abroad. It is not extendable in any useful sense and missing it forfeits foreign rights where the invention has been disclosed.
Which route, and what does it buy? Direct national filings, the treaty route, or a mixture. The treaty route buys eighteen additional months and a search report; it does not buy a patent.
Which countries, and why? Market matters less than manufacturing and enforcement, and the country list drives a twenty-year cost.

If you read only one thing, read The Priority Chain. The dates it describes are the whole of international patent practice.

The Priority Right

What it is. A right to claim the filing date of an earlier application in a treaty country, for an application filed within twelve months. 35 U.S.C. § 119 supplies the domestic side.

What it does. It makes intervening disclosures, publications, and third-party filings irrelevant to the later-filed application, which is the entire point.

What it covers. Only subject matter the priority application actually describes and enables. A thin provisional confers priority on thin subject matter, and new matter in the later filing gets the later date.

The deadline. Twelve months from the earliest filing. There is a narrow restoration mechanism in some jurisdictions for unintentional delay, and it is unreliable and not a plan.

The trap. A company that filed a provisional and converted it domestically at twelve months frequently believes it has twelve months from the conversion. It does not. The clock runs from the provisional.

What happens if it passes. Foreign filing is still possible; the priority claim is not. Any disclosure, sale, or publication in the intervening period becomes prior art, and in absolute-novelty jurisdictions the applicant's own disclosure is fatal.

Absolute Novelty, and Why the Grace Period Is Not a Plan

The domestic rule. 35 U.S.C. § 102(b) supplies a one-year grace period for the inventor's own disclosures and for third-party disclosures that follow them.

The rule nearly everywhere else. Absolute novelty. Any public disclosure before the priority date destroys novelty, including the inventor's own. A few jurisdictions have narrow grace periods, generally limited to specified circumstances such as display at recognized international exhibitions or disclosure obtained unlawfully.

What this means practically. A conference presentation, a published paper, a product demonstration, a trade show booth, or a public sale destroys foreign rights immediately. The domestic grace period saves the domestic application and nothing else.

Brennerman's poster session. Fourteen months ago, which is outside even the domestic grace period unless the application filed eleven months ago claims priority to something earlier. If the domestic filing is the first filing and it postdates the poster by three months, the domestic application is within the grace period and foreign rights are gone. This is discovered constantly and it is not recoverable.

The discipline. File before disclosing. Route conference abstracts, papers, demonstrations, and trade show materials past counsel before submission. This single process control preserves more foreign value than any filing strategy.

Route One: Direct Filing

What it is. Filing national applications in each country within the twelve-month priority window.

When it makes sense. A small, certain country list. Where speed to grant matters. Where the treaty route's fees exceed the cost of two or three direct filings.

What it costs. Local associates, translations, and official fees, all at twelve months.

The disadvantage. The country decision must be made at twelve months, when the company usually knows least about which markets will matter.

Route Two: The Patent Cooperation Treaty

What it is. A single international application, filed within the priority year, that preserves the right to enter the national phase in over one hundred fifty contracting states.

What it buys. Time — thirty months from the priority date to decide which countries, rather than twelve. And information: an international search report and a written opinion on patentability, arriving around sixteen to eighteen months, which informs the country decision and the prosecution strategy.

What it does not buy. A patent. There is no international patent. The application must enter the national phase in each country and be prosecuted there.

The sequence. File the international application by twelve months. Receive the search report and written opinion. The application publishes at eighteen months. Optionally file a demand for international preliminary examination under Chapter II, producing a further opinion. Enter the national phase by thirty months, or thirty-one in some jurisdictions.

The Chapter II demand. Buys a second examination round and a chance to amend before the national phase. Its value has declined as most jurisdictions now permit amendment on entry, and it remains useful where the written opinion was negative and an amendment would change it.

The cost profile. The treaty route front-loads a moderate fee and defers the large expenses — translations, local associates, national fees — by eighteen months. For a company that does not yet know its markets, that deferral is usually worth more than it costs.

The domestic requirement. A foreign filing license is required before filing abroad on an invention made domestically. 35 U.S.C. § 184. Filing without one invalidates the patent under 35 U.S.C. § 185. The license is typically granted automatically with the domestic filing receipt, and the trap is filing abroad first.

Route Three: The Mixture

Most sophisticated programs use both.

Direct file where speed matters — a market where a competitor is already selling, or a jurisdiction with a utility model offering fast, cheap protection.

Use the treaty for everything else, preserving the option and deferring the cost.

Consider a regional application where one exists, covering multiple states through a single prosecution with validation in selected states at grant.

Consider a second priority filing where development continued after the first filing, capturing improvements with a new date while the original priority runs.

Country Selection

The question is not where the market is. It is where a patent would do something.

Where the product is manufactured. An injunction against manufacture stops supply globally. This is the highest-value jurisdiction and it is routinely omitted in favor of the largest market.

Where competitors manufacture. The same logic, applied to the party the patent would be asserted against.

Where the product is sold in volume. The obvious answer, and it is one input among several.

Where enforcement actually works. Speed, cost, injunction availability, and damages practice differ enormously. A patent in a jurisdiction where enforcement takes eight years and produces nominal damages is a certificate.

Where customers demand it. Licensees and distributors frequently require local protection.

Where the company will need freedom to operate, because a patent is a negotiating asset even where it is not asserted.

Where the exclusion is available at the border. Customs recordation and border measures make a patent useful against imports in a way district court practice does not.

The trap. Filing in a long list of countries because they were on a form, then abandoning half of them at the first annuity because nobody budgeted the recurring cost.

What It Costs

The budget is dominated by two lines that clients do not anticipate.

Translations. A specification of any length translated into several languages is a substantial cost per jurisdiction, incurred at national phase entry. It is the single largest one-time expense in international filing.

Annuities. Most jurisdictions charge annual maintenance fees from an early year, escalating over the term. Across ten countries for twenty years, annuities exceed every other cost in the program combined.

Local associates. Required in nearly every jurisdiction, charging for entry, prosecution, and each response.

Official fees. Filing, examination, grant, and validation where applicable.

The planning implication. The country list should be built against a twenty-year cost model rather than against a filing budget. A company that files in twelve countries and can afford annuities in four has wasted the translations for eight.

The pruning discipline. Every annuity is a decision. An annual review deciding what to maintain and what to abandon is what keeps an international portfolio affordable. See Patent Portfolio Management Toolkit.

Regional Systems and Utility Models

Regional patents. Several regions permit a single application and prosecution covering many states, with the granted patent validated in selected states. The efficiency is in prosecution; the cost returns at validation, where translations and local agents multiply.

Unitary effect, where available, replaces validation in participating states with a single right and a single renewal, which changes the arithmetic substantially and carries a single point of failure in central revocation.

Utility models. Available in a number of jurisdictions, offering shorter terms, lower thresholds, faster registration, and lower cost. They are frequently unexamined, which makes them fast to obtain and vulnerable when asserted. For a product with a short commercial life in a jurisdiction where utility models are enforceable, they are efficient.

Design registrations protect appearance rather than function and register quickly in most jurisdictions. Where the product's distinctiveness is visual, they are the cheapest useful right available. See Three Ways to Own a Shape.

Prosecution Differences That Matter

Claim format. Two-part claim form, reference numerals, and multiple dependency conventions differ, and claims drafted for one office require adaptation.

Added matter is treated strictly in many jurisdictions. An amendment finding support only in a combination of passages may be refused where a domestic examiner would allow it, which makes the original disclosure more important abroad than at home.

Unity of invention is applied more strictly than domestic restriction practice, and divisional filings carry their own deadlines.

Opposition. Several systems permit third-party opposition within a window after grant, which is a cheaper and faster challenge than most litigation.

Examination requests. Some jurisdictions require an affirmative request within a deadline, and failing to request examination abandons the application.

Working requirements and compulsory licensing exist in some jurisdictions and require attention where the patent will not be practiced locally.

Translation errors matter. A claim mistranslated is a claim with a different scope, and the correction mechanisms are narrow.

Brennerman's Four Questions, Answered

The cost. There is no single number, because it depends entirely on the country list and on the twenty-year annuity profile. The honest answer is a model: pick three, five, and ten-country scenarios; price translations at entry and annuities across the term; and let the business decide against a real curve rather than a rumor.

The poster session. If the domestic application filed eleven months ago is the first filing and the poster preceded it by three months, foreign rights in absolute-novelty jurisdictions are gone. Confirm whether anything earlier was filed, confirm exactly what the poster disclosed, and check whether any narrow exhibition-based grace period applies in a jurisdiction that matters. Then fix the process, because this will happen again otherwise.

The manufacturing question. File where the product is made and where it is assembled, not only where it is sold. An injunction against manufacture stops supply everywhere, and it is the highest-leverage jurisdiction in the whole list.

"File internationally." There is no international patent. What exists is a treaty application that defers the country decision by eighteen months and produces a search report. Filing it within the next two weeks preserves every option; not filing it forecloses them.

Building the Program

A filing calendar keyed to the priority date, with the twelve-month, eighteen-month, thirty-month, and annuity dates entered in two systems.

A disclosure control routing conference abstracts, papers, demonstrations, and trade show materials past counsel before submission. The highest-return process control in the entire program.

A country model built once and refreshed annually, pricing three scenarios against a twenty-year curve.

A foreign filing license check in the pre-filing workflow.

An associate network with known, predictable pricing, because associate cost varies by an order of magnitude and it compounds across a portfolio.

A translation strategy. Claim-only translations where permitted, deferred full translations where the rules allow, and a consistent glossary across a family.

An annual annuity review deciding, jurisdiction by jurisdiction, what to keep.

A written record of the country decisions, because a buyer's counsel will ask why the portfolio looks the way it does.

The Deadline Map

International patent practice is a sequence of dates, and knowing which are hard and which are soft is most of the skill.

Day zero. The earliest filing — usually a provisional. Everything else counts from here.

Twelve months. The Paris priority deadline. File the treaty application, or file direct nationals, or lose the priority claim. Hard. Restoration exists in some jurisdictions on an unintentional-delay standard and it is unreliable.

Twelve months, domestic. Convert the provisional under 35 U.S.C. § 111 or lose the domestic priority claim. Same day, separate action, and it is routinely conflated with the foreign deadline.

Sixteen to eighteen months. The international search report and written opinion arrive. This is the information the country decision should use.

Eighteen months. Publication under 35 U.S.C. § 122 and its international equivalent. The application becomes visible to competitors, and provisional rights open under 35 U.S.C. § 154(d) where the issued claims end up substantially identical.

Twenty-two months. The Chapter II demand deadline, where a second examination round is wanted.

Thirty months. National phase entry under 35 U.S.C. § 371 and its foreign equivalents, with thirty-one months in some jurisdictions. Hard, jurisdiction by jurisdiction, and this is the date on which most international portfolios are actually decided.

Entry plus varying periods. Examination requests where an affirmative request is required, translations where deferred, and local formalities.

Annuities. Beginning in an early year in most jurisdictions and running annually thereafter, escalating.

The rule. Enter every one of these in two independent systems, and calendar the decision date rather than the deadline. A country list assembled the week national phase entry is due is a country list assembled by whoever answers the phone.

Working With Foreign Associates

The associate network determines both cost and quality, and it is managed casually more often than it should be.

Instruct precisely. An associate given the application and told to enter the national phase will do exactly that, at whatever claim scope arrives. An associate told which claims matter, what the search report said, and what the commercial objective is will prosecute toward it.

Fix the pricing. Entry, response, and grant, quoted in advance. Associate cost varies by an order of magnitude across firms in the same city and it compounds across a portfolio and across twenty years.

Consolidate where possible. A single firm covering a region reduces coordination overhead and produces consistency in claim language across jurisdictions.

Ask about local practice before amending. Added-matter rules are stricter in many jurisdictions, and an amendment that would be routine domestically can be refused abroad. The associate knows this and will not volunteer it unless asked.

Keep the claim sets consistent across a family unless there is a reason to diverge. Divergence happens by accident when each associate amends independently, and it produces a family whose scope nobody can describe.

Maintain a glossary for translations, so that a term rendered one way in one jurisdiction is not rendered differently in another.

Report the search results back. Art cited by a foreign examiner is material to the domestic application under 37 C.F.R. § 1.56, and the flow of information in that direction fails routinely.

Enforcement Asymmetry

A patent is only as useful as the forum that enforces it, and forums differ more than most clients expect.

Speed. Some jurisdictions reach a merits decision in under a year; others take five or more. A fast forum changes settlement dynamics for a whole portfolio, because the credible threat of a near-term injunction is worth more than a distant damages award.

Injunction availability. Where injunctive relief follows a finding of infringement as a matter of course, a patent is a much stronger instrument than where it is discretionary and rarely granted against a non-competitor.

Bifurcation. Some systems try infringement and validity separately, in different courts on different timelines. That can produce a period during which an injunction is in force against a patent later found invalid, which is a real commercial risk for a defendant and a real lever for a patentee.

Damages practice. Some jurisdictions award damages calibrated to actual loss with limited discovery; others permit substantial recoveries with apportionment fights resembling domestic practice.

Discovery. Broad document discovery is unusual outside a small number of systems, which makes proving infringement harder where the evidence sits inside the defendant.

Border measures. Customs recordation and seizure procedures give a patent leverage against imports that court practice does not, and they are cheap relative to litigation.

Opposition and revocation. Post-grant opposition windows offer challengers a fast, inexpensive route, which means a patent in those jurisdictions faces a predictable early test.

The planning consequence. File where enforcement works, not only where sales occur. A portfolio concentrated in slow, injunction-averse jurisdictions is expensive to maintain and hard to use, and the country model should weight forum quality alongside market size.

Portfolio Shapes That Work

Three patterns cover most well-run international programs.

The narrow spine. Three to five jurisdictions chosen for manufacturing, enforcement quality, and the largest market. Every family filed in all of them. Simple, affordable, and it produces a portfolio the company can actually use.

The tiered portfolio. A core set for every family, plus an extended set for the two or three families covering flagship products. This is the common shape for companies with a mix of important and incremental inventions, and it requires a triage discipline at the thirty-month decision.

The market-following portfolio. Filings added as markets open, using the treaty route to defer and a policy of entering the national phase in a jurisdiction only when a commercial commitment exists there. Cheapest and it forfeits protection in markets that develop after thirty months.

What does not work. Filing broadly at entry and abandoning at the first annuity wave, which pays for translations in jurisdictions the company was never going to maintain. That is the single most common waste in international patent budgets and it is avoided by building the twenty-year cost model before the country list.

Drafting for Foreign Filing

An application drafted only for domestic examination creates problems abroad that cannot be fixed later.

Added matter is strict. Many jurisdictions refuse an amendment whose support comes from combining separate passages, or from an implicit teaching a domestic examiner would accept. The consequence is that every claim the family might eventually want must have literal, locatable support in the specification as filed.

Provide basis for intermediate generalizations. If the specification describes a feature only within a detailed embodiment, a claim to that feature standing alone may be unsupported abroad. State the feature independently as well.

Include the ranges and the alternatives explicitly. A range disclosed only by example does not support a claim to the range in strict jurisdictions.

Provide a clear statement of the technical problem and the technical solution. Several systems assess inventive step through a problem-and-solution framework, and a specification that frames the invention that way prosecutes more easily.

Include claim-like statements of the invention in the description, which is conventional in some systems and provides literal support for later amendments everywhere.

Watch the drawings. Reference numerals in the claims are expected in some jurisdictions and the drawing conventions differ. 37 C.F.R. § 1.84 governs the domestic requirements and foreign formats vary.

Avoid domestic-only claim forms where a family will travel — omnibus claims, certain functional formats, and claim types unavailable in some systems.

Mind the unity requirement. Foreign practice applies unity of invention more strictly than domestic restriction practice, and an application claiming several inventions will be divided at the applicant's cost.

And keep the specification long. The disclosure cannot be added to after filing, it is the ceiling on every claim in every jurisdiction, and abroad it is a harder ceiling than at home. See Drafting a Patent Specification That Survives.

The Thirty-Month Decision

National phase entry is where an international program is actually built, and the decision deserves a structured process rather than a scramble.

Start at month twenty-four. Six months before the deadline, with the search report and written opinion in hand.

Read the written opinion honestly. A negative opinion on novelty or inventive step will be echoed by most examining offices, and it should shrink the country list rather than be ignored.

Update the commercial picture. Which markets have actually developed, where the product is now manufactured, who the competitors turned out to be, and which customers have asked for local protection. This information did not exist at twelve months, and having it is the entire value of the deferral.

Run the twenty-year cost model against the candidate list, including translations at entry and annuities across the term.

Decide per family, not per company. A flagship family may justify ten jurisdictions where an incremental one justifies two, and a uniform country policy overspends on the second and underspends on the first.

Consider the regional option where one exists, comparing single prosecution plus validation against direct national filings for the same coverage.

Consider utility models in jurisdictions where they are available and enforceable, particularly for products with short commercial lives.

Record the reasoning. A written decision, per family, naming the jurisdictions chosen and the ones declined and why. A buyer's counsel will ask, and "that is what we always file" is not an answer.

Then calendar what entry triggers — examination requests, translation deadlines, and the first annuity — because the work does not stop at entry and the second wave of deadlines is where portfolios are lost by inattention.

Where the Money Is Actually Wasted

Four patterns account for most of the waste in international patent budgets, and each is avoidable.

Filing where the company will not maintain. Translations paid at entry in jurisdictions abandoned at the first annuity. The fix is the twenty-year model, built before the country list.

Maintaining what nobody uses. Families kept alive out of inertia, on products discontinued years earlier, in jurisdictions the company left. The fix is the annual review, with an affirmative decision required to keep rather than to abandon.

Prosecuting to allowance regardless of scope. An associate instructed only to obtain grant will accept whatever claims the examiner offers, and a granted patent with claims nobody can assert costs the same annuities as a useful one. The fix is instructing associates on the commercial objective and being willing to abandon rather than narrow past usefulness.

Uncoordinated claim sets. Each associate amending independently produces a family whose scope varies by jurisdiction in ways nobody intended and nobody can explain to a licensee. The fix is a coordinating counsel who reviews every amendment across the family.

And one that is not waste. Filing in a jurisdiction where the company does not sell, because a competitor manufactures there. That looks like waste on a market-based analysis and it is frequently the most valuable filing in the portfolio.

One More Thing About Disclosure

The single highest-return control in an international program costs nothing and belongs to a function that does not report to legal.

Engineers submit conference abstracts. Marketing books trade show booths. Sales demonstrates prototypes. Business development shares specifications with prospective partners. Each of these is a public disclosure, each destroys foreign rights in absolute-novelty jurisdictions the moment it occurs, and none of the people doing them thinks of it as a legal event.

A single routing rule — anything going outside the company that describes an unfiled invention goes past counsel first — preserves more international value than any filing strategy, any associate relationship, and any country model. It requires a short form, a fast answer, and one briefing a year to the four functions that generate disclosures.

Companies discover this the way Brennerman did: eleven months into a priority year, with a poster session in the past and no way back.

A Suggested Reading Path

If the deadline is approaching:

If you are building the strategy:

If you are drafting with foreign filing in mind:

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 119 | Foreign and provisional priority; the twelve-month right | | 35 U.S.C. § 120 | Benefit of an earlier domestic application | | 35 U.S.C. § 102 | Novelty; the domestic grace period | | 35 U.S.C. § 111 | Application; provisional and non-provisional | | 35 U.S.C. § 112 | Disclosure; support for foreign amendments | | 35 U.S.C. § 122 | Publication at eighteen months | | 35 U.S.C. § 184 | Foreign filing license | | 35 U.S.C. § 185 | Patent barred for filing without a license | | 35 U.S.C. § 351 | Treaty definitions | | 35 U.S.C. § 363 | International application as a domestic filing | | 35 U.S.C. § 365 | Right of priority from an international application | | 35 U.S.C. § 371 | National stage entry | | 35 U.S.C. § 154 | Term and adjustment | | 35 U.S.C. § 41 | Maintenance fees | | 35 U.S.C. § 261 | Assignment; recordal abroad | | 37 C.F.R. § 1.56 | Duty of disclosure; foreign search results | | 37 C.F.R. § 1.97 | Disclosure timing for foreign art |

Forms and Templates

The Portfolio Inventory Template is the working document of an international program, tracking family, jurisdiction, status, next deadline, annuity date, and the annual keep-or-abandon decision — and it is the single artifact that prevents the two most common failures, a missed national phase entry and an unbudgeted annuity wave. The Assignment Agreement Template supplies the present-tense assignment language, which matters more abroad than at home because several jurisdictions require recorded assignment before an applicant can act. The Office Action Response Template adapts to foreign practice with the caution that added-matter rules are stricter abroad, so amendments must be traceable to specific passages. The License Agreement Template matters because territorial licensing is how most international portfolios actually generate revenue.

Related Toolkits and Checklists

For the doctrinal groundwork the international decision rests on, the Patent Fundamentals Toolkit covers eligibility, novelty, obviousness, and disclosure. For the domestic prosecution running in parallel, the Patent Prosecution Toolkit supplies the sequence and the docketing discipline. For deciding which foreign families to maintain, the Patent Portfolio Management Toolkit supplies the pruning method. And where the product implements a standard, the Standard-Essential Patents and FRAND Toolkit covers a licensing question that no filing strategy answers.